Literature DB >> 9607614

Alpha-lipoic acid in liver metabolism and disease.

J Bustamante1, J K Lodge, L Marcocci, H J Tritschler, L Packer, B H Rihn.   

Abstract

R-alpha-Lipoic acid is found naturally occurring as a prosthetic group in alpha-keto acid dehydrogenase complexes of the mitochondria, and as such plays a fundamental role in metabolism. Although this has been known for decades, only recently has free supplemented alpha-lipoic acid been found to affect cellular metabolic processes in vitro, as it has the ability to alter the redox status of cells and interact with thiols and other antioxidants. Therefore, it appears that this compound has important therapeutic potential in conditions where oxidative stress is involved. Early case studies with alpha-lipoic acid were performed with little knowledge of the action of alpha-lipoic acid at a cellular level, but with the rationale that because the naturally occurring protein bound form of alpha-lipoic acid has a pivotal role in metabolism, that supplementation may have some beneficial effect. Such studies sought to evaluate the effect of supplemented alpha-lipoic acid, using low doses, on lipid or carbohydrate metabolism, but little or no effect was observed. A common response in these trials was an increase in glucose uptake, but increased plasma levels of pyruvate and lactate were also observed, suggesting that an inhibitory effect on the pyruvate dehydrogenase complex was occurring. During the same period, alpha-lipoic acid was also used as a therapeutic agent in a number of conditions relating to liver disease, including alcohol-induced damage, mushroom poisoning, metal intoxification, and CCl4 poisoning. Alpha-Lipoic acid supplementation was successful in the treatment for these conditions in many cases. Experimental studies and clinical trials in the last 5 years using high doses of alpha-lipoic acid (600 mg in humans) have provided new and consistent evidence for the therapeutic role of antioxidant alpha-lipoic acid in the treatment of insulin resistance and diabetic polyneuropathy. This new insight should encourage clinicians to use alpha-lipoic acid in diseases affecting liver in which oxidative stress is involved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607614     DOI: 10.1016/s0891-5849(97)00371-7

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  56 in total

1.  Regulation of the activity of choline acetyl transferase by lipoic acid.

Authors:  N Haugaard; R M Levin
Journal:  Mol Cell Biochem       Date:  2000-10       Impact factor: 3.396

2.  Activation of choline acetyl transferase by dihydrolipoic acid.

Authors:  Niels Haugaard; Robert M Levin
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

3.  Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells.

Authors:  Margareta Berggren; Sivanandane Sittadjody; Zuohe Song; Jean-Louis Samira; Randy Burd; Emmanuelle J Meuillet
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

Review 4.  The sodium/multivitamin transporter: a multipotent system with therapeutic implications.

Authors:  Matthias Quick; Lei Shi
Journal:  Vitam Horm       Date:  2015-03-07       Impact factor: 3.421

5.  Interaction of α-Lipoic Acid with the Human Na+/Multivitamin Transporter (hSMVT).

Authors:  Britta Zehnpfennig; Pattama Wiriyasermkul; David A Carlson; Matthias Quick
Journal:  J Biol Chem       Date:  2015-05-13       Impact factor: 5.157

6.  Protective effects of a novel synthetic α-lipoic acid-decursinol hybrid compound in experimentally induced transient cerebral ischemia.

Authors:  Tae Hun Lee; Joon Ha Park; Jong-Dai Kim; Jae-Chul Lee; In Hye Kim; Yongbae Yim; Seul Ki Lee; Bing Chun Yan; Ji Hyeon Ahn; Choong Hyun Lee; Ki-Yeon Yoo; Jung Hoon Choi; In Koo Hwang; Jeong Ho Park; Moo-Ho Won
Journal:  Cell Mol Neurobiol       Date:  2012-07-20       Impact factor: 5.046

7.  Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial.

Authors:  Ezra Gabbay; Ehud Zigmond; Orit Pappo; Nila Hemed; Mina Rowe; George Zabrecky; Robert Cohen; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

8.  Effect of DHLA on response of isolated rat urinary bladder to repetitive field stimulation.

Authors:  Robert M Levin; Abby Borow; Sheila S Levin; Niels Haugaard
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

9.  Prevention of high-fat diet-induced muscular lipid accumulation in rats by alpha lipoic acid is not mediated by AMPK activation.

Authors:  Silvie Timmers; Johan de Vogel-van den Bosch; Mhairi C Towler; Gert Schaart; Esther Moonen-Kornips; Ronald P Mensink; Matthijs K Hesselink; D Grahame Hardie; Patrick Schrauwen
Journal:  J Lipid Res       Date:  2009-08-18       Impact factor: 5.922

10.  Adverse cardiac responses to alpha-lipoic acid in a rat-diabetic model: possible mechanisms?

Authors:  Nouf M Al-Rasheed; Nawal M Al-Rasheed; Hala A Attia; Iman H Hasan; Maha Al-Amin; Hanaa Al-Ajmi; Raeesa A Mohamad
Journal:  J Physiol Biochem       Date:  2013-04-18       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.